Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Archemix and Nuvelo have expanded their anticoagulation drug development pact. Under the new agreement, Archemix will discover short-acting aptamers targeting the coagulation cascade, and Nuvelo will spearhead their development and commercialization. Nuvelo will make an up-front payment of $4 million, will fund Archemix' research in short-acting aptamers for the next three years, and may invest up to $10 million in Archemix when it goes public. The companies had previously collaborated on Archemix' thrombin inhibitor ARC183, which was dropped from clinical development due to low potency.
This article has been sent to the following recipient: